HRP20250774T1 - Umreženi polimeri za kationsku izmjenu, pripravci i upotreba u liječenju hiperkalemije - Google Patents

Umreženi polimeri za kationsku izmjenu, pripravci i upotreba u liječenju hiperkalemije

Info

Publication number
HRP20250774T1
HRP20250774T1 HRP20250774TT HRP20250774T HRP20250774T1 HR P20250774 T1 HRP20250774 T1 HR P20250774T1 HR P20250774T T HRP20250774T T HR P20250774TT HR P20250774 T HRP20250774 T HR P20250774T HR P20250774 T1 HRP20250774 T1 HR P20250774T1
Authority
HR
Croatia
Prior art keywords
calcium
sugar alcohol
fluoroacrylate
divinylbenzene
linear sugar
Prior art date
Application number
HRP20250774TT
Other languages
English (en)
Croatian (hr)
Inventor
Han-Ting Chang
Dominique Charmot
Mingjun Liu
Werner Struever
Paul Mansky
Detlef Albrecht
Michael Burdick
Eric Connor
Sherin Halfon
I-Zu Huang
Ramakrishnan Chidambaram
Jonathan Mills
Original Assignee
Vifor (International) Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41707686&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20250774(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vifor (International) Ltd. filed Critical Vifor (International) Ltd.
Publication of HRP20250774T1 publication Critical patent/HRP20250774T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/16—Organic material
    • B01J39/18—Macromolecular compounds
    • B01J39/20—Macromolecular compounds obtained by reactions only involving unsaturated carbon-to-carbon bonds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/10—Esters
    • C08F220/22—Esters containing halogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F212/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring
    • C08F212/34—Monomers containing two or more unsaturated aliphatic radicals
    • C08F212/36—Divinylbenzene

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
HRP20250774TT 2008-08-22 2009-08-22 Umreženi polimeri za kationsku izmjenu, pripravci i upotreba u liječenju hiperkalemije HRP20250774T1 (hr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US9111008P 2008-08-22 2008-08-22
US9112508P 2008-08-22 2008-08-22
US9109708P 2008-08-22 2008-08-22
US16589909P 2009-04-01 2009-04-01
US16589409P 2009-04-01 2009-04-01
US16590509P 2009-04-02 2009-04-02
EP22211737.6A EP4201408B1 (en) 2008-08-22 2009-08-22 Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia

Publications (1)

Publication Number Publication Date
HRP20250774T1 true HRP20250774T1 (hr) 2025-08-29

Family

ID=41707686

Family Applications (4)

Application Number Title Priority Date Filing Date
HRP20250774TT HRP20250774T1 (hr) 2008-08-22 2009-08-22 Umreženi polimeri za kationsku izmjenu, pripravci i upotreba u liječenju hiperkalemije
HRP20230091TT HRP20230091T1 (hr) 2008-08-22 2009-08-22 Umreženi polimeri za kationsku izmjenu, sastavi i upotreba u liječenju hiperkalemije
HRP20150955TT HRP20150955T1 (hr) 2008-08-22 2009-08-22 Umreženi polimeri za kationsku izmjenu, pripravci i uporaba za lijeäśenje hiperkalemije
HRP20181961TT HRP20181961T1 (hr) 2008-08-22 2018-11-22 Pripravci koji sadrže umrežene polimere za kationsku izmjenu i primjena u liječenju hiperkalijemije

Family Applications After (3)

Application Number Title Priority Date Filing Date
HRP20230091TT HRP20230091T1 (hr) 2008-08-22 2009-08-22 Umreženi polimeri za kationsku izmjenu, sastavi i upotreba u liječenju hiperkalemije
HRP20150955TT HRP20150955T1 (hr) 2008-08-22 2009-08-22 Umreženi polimeri za kationsku izmjenu, pripravci i uporaba za lijeäśenje hiperkalemije
HRP20181961TT HRP20181961T1 (hr) 2008-08-22 2018-11-22 Pripravci koji sadrže umrežene polimere za kationsku izmjenu i primjena u liječenju hiperkalijemije

Country Status (26)

Country Link
US (4) US20110236340A1 (enExample)
EP (4) EP2365988B2 (enExample)
JP (7) JP5756403B2 (enExample)
KR (5) KR101928973B1 (enExample)
CN (2) CN103919792B (enExample)
AU (1) AU2009282721B2 (enExample)
BR (1) BRPI0917853C1 (enExample)
CA (1) CA2735058C (enExample)
CY (3) CY2018002I1 (enExample)
DE (1) DE112009002063T5 (enExample)
DK (3) DK2365988T4 (enExample)
ES (4) ES2545887T5 (enExample)
FI (1) FI3431094T3 (enExample)
GB (4) GB2475657B (enExample)
HR (4) HRP20250774T1 (enExample)
HU (4) HUE071829T2 (enExample)
LT (4) LT2957286T (enExample)
LU (1) LUC00094I2 (enExample)
MX (3) MX389664B (enExample)
NL (1) NL300962I2 (enExample)
NO (2) NO2018004I1 (enExample)
PL (4) PL3431094T3 (enExample)
PT (3) PT2365988E (enExample)
SI (2) SI3431094T1 (enExample)
SM (2) SMT201800660T1 (enExample)
WO (1) WO2010022383A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8574716B2 (en) * 2006-01-23 2013-11-05 Hitachi Chemical Co., Ltd. Ionic polymer devices and methods of fabricating the same
WO2010022380A2 (en) 2008-08-22 2010-02-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
CN103919792B (zh) 2008-08-22 2018-03-09 瑞立普萨公司 交联阳离子交换聚合物、组合物及在治疗方法高钾血症中的应用
TR201807469T4 (tr) * 2010-03-20 2018-06-21 Relypsa Inc Polifloroakrilat partikülleri hazırlamaya yönelik kesintisiz işlem.
SMT201900037T1 (it) 2011-02-11 2019-02-28 Zs Pharma Inc Uso di un silicato di zirconio per il trattamento di iperkaliemia
RU2618220C2 (ru) * 2011-06-27 2017-05-03 Релипса, Инк. Способ преобразования полимера сложного эфира в полимерную кислоту
CN103717567A (zh) 2011-06-27 2014-04-09 瑞立普萨公司 丙烯酸酯及衍生物的氟化
US20150196585A1 (en) * 2012-07-19 2015-07-16 Relypsa, Inc. Compositions comprising crosslinked cation-binding polymers and uses thereof
EP2882798B1 (en) * 2012-08-09 2019-05-08 Patheon Austria GmbH & Co KG Process for drying polymeric materials
AU2013329451B2 (en) * 2012-10-08 2018-08-09 Vifor (International) Ltd. Potassium-binding agents for treating hypertension and hyperkalemia
US10695365B2 (en) 2012-10-22 2020-06-30 ZS Pharma, Inc. Microporous zirconium silicate for the treatment of hyperkalemia
CA2908641C (en) 2013-04-05 2022-10-18 ZS Pharma, Inc. Microporous zirconium silicate and diuretics for the reduction of potassium and treatment of chronic kidney and/or chronic heart disease
ES2800167T3 (es) * 2014-12-23 2020-12-28 Ardelyx Inc Composiciones y métodos para tratar hiperpotasemia
WO2017040520A1 (en) 2015-08-31 2017-03-09 Hitachi Chemical Co., Ltd. Molecular methods for assessing urothelial disease
US9592253B1 (en) 2015-10-14 2017-03-14 ZS Pharma, Inc. Extended use zirconium silicate compositions and methods of use thereof
ITUB20159278A1 (it) 2015-12-23 2017-06-23 Rjw Pharma Llc Procedimento per la sintesi di patiromer
WO2019220450A1 (en) 2018-05-16 2019-11-21 Solara Active Pharma Sciences Limited Process for preparation of patiromer
CN113557024A (zh) * 2019-03-13 2021-10-26 阿斯利康(瑞典)有限公司 用于血液透析患者中使用的钾结合剂
US12441677B2 (en) 2019-11-14 2025-10-14 Vifor (International) Ltd. One step synthesis for alkyl 2-fluoroacrylates
CN115427383B (zh) * 2020-03-27 2025-08-26 维福(国际)有限公司 2-氟丙烯酸甲酯的合成
ES2985514T3 (es) * 2021-09-13 2024-11-06 Waterstone Pharmaceuticals Wuhan Co Ltd Medicamento polimérico para tratar la hiperpotasemia y método de preparación del mismo
US20240139234A1 (en) * 2021-11-17 2024-05-02 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Pharmaceutical polymer for treating hyperkalemia and preparation method thereof
CN114369729B (zh) * 2021-12-28 2023-11-03 江苏容汇通用锂业股份有限公司 一种利用锂矿渣进行浸出液除钾的工艺
CN114394918B (zh) * 2022-01-19 2023-10-20 罗长青 一种2-[[三(羟甲基)甲基]氨基]乙磺酸的制备方法

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2611730A (en) * 1950-09-02 1952-09-23 Simth Kline & French Lab Medical preparation for reducing the body level of sodium
US2909462A (en) * 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3499960A (en) * 1965-01-25 1970-03-10 Merck & Co Inc Palatable coated particles of an anion exchange resin
NL137053C (enExample) † 1967-01-30
FR2171934B1 (enExample) * 1972-02-16 1974-09-13 Rhone Poulenc Sa
US3974272A (en) * 1972-09-01 1976-08-10 Merck & Co., Inc. Palatable cholestyramine coacervate compositions
US4143130A (en) * 1977-08-29 1979-03-06 Warren-Teed Laboratories, Inc. Method for treating kidney stones
US4470975A (en) * 1977-10-21 1984-09-11 The Johns Hopkins University Method and composition for the elimination of water from an animal body
US4380590A (en) * 1978-09-19 1983-04-19 Rohm And Haas Company Emulsion copolymer cation exchange resins
DE2846187A1 (de) † 1978-10-24 1980-05-08 Bayer Ag Kunstharze auf basis vernetzter mischpolymerisate aus mono- und polyvinylverbindungen
JPS6090243A (ja) * 1983-10-25 1985-05-21 Nitto Boseki Co Ltd 小球状モノアリルアミン橋かけ重合体の製造方法
US4747881A (en) * 1985-02-05 1988-05-31 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
US5186937A (en) * 1985-06-07 1993-02-16 A.E.C. Societe De Chimie Organique Et Biologique Composition for feeding ruminants
IT1190349B (it) * 1986-06-16 1988-02-16 Prodotti Formenti Srl Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle
JPS63218713A (ja) * 1987-02-17 1988-09-12 Daikin Ind Ltd α−フルオロアクリル酸系重合体ならびに用途
US4837015A (en) * 1987-03-05 1989-06-06 Carolina Medical Products Company, Inc. Alkali metal ion-charged, cation exchanger and use thereof to adjust sodium, potassium and calcium body fluid levels
GB8817015D0 (en) * 1988-07-16 1988-08-17 Reckitt & Colmann Prod Ltd Method of treatment
GB8829088D0 (en) † 1988-12-13 1989-01-25 Smith Kline French Lab Compounds
US5236701A (en) * 1989-07-19 1993-08-17 Lowchol Scientific Inc. Ingestible hydrophilic polymeric amines useful for lowering blood cholesterol
DE3928990A1 (de) 1989-09-01 1991-03-07 Bayer Ag Verfahren zur herstellung von (alpha)-fluoroacrylsaeurederivaten
US5112993A (en) 1989-11-14 1992-05-12 E. I. Du Pont De Nemours And Company Process for the preparation of difluoromaleic anhydride
US5091175A (en) * 1990-05-14 1992-02-25 Erbamont Inc. Pharmaceutical composition containing bile acid sequestrant enclosed in a size-exclusion membrane
ES2070307T3 (es) * 1990-07-04 1995-06-01 Marcin Krotkiewski Una preparacion para el tratamiento de la hipertension.
US5162110A (en) * 1990-12-19 1992-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Binding theophylline to ion exchange resins
US5281631A (en) * 1991-12-20 1994-01-25 Arch Development Corp. Phosphonic acid based ion exchange resins
DE69306844T2 (de) † 1992-04-10 1997-07-10 Mitsubishi Chem Corp Verfahren zur Herstellung von kugelförmigen vernetzten Acrylnitril-Copolymerisaten
HUT72658A (en) * 1992-08-20 1996-05-28 Du Pont Crosslinked polymeric ammonium salts and pharmaceutical compositions containing them
US5487888A (en) * 1993-05-20 1996-01-30 Geltex, Inc. Iron-binding polymers for oral administration
US5607669A (en) * 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5618530A (en) * 1994-06-10 1997-04-08 Geltex Pharmaceuticals, Inc. Hydrophobic amine polymer sequestrant and method of cholesterol depletion
US5667775A (en) * 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
JPH09506342A (ja) * 1993-11-25 1997-06-24 サルテルナテ・ベー・ブイ 一価カチオンに結合する粒子、並びにナトリウムおよび／またはカリウムイオンを捕捉して除去するための上記粒子の使用および方法
TW474813B (en) * 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
US6623759B2 (en) * 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
US5935599A (en) * 1996-10-28 1999-08-10 The Board Of Trustees Of The University Of Illinois Polymer-associated liposomes for drug delivery and method of manufacturing the same
US6280717B1 (en) * 1998-07-31 2001-08-28 Nikken Chemicals Co., Ltd. Cation exchange resin preparation
US6294163B1 (en) * 1998-10-02 2001-09-25 Geltex Pharmaceuticals, Inc. Polymers containing guanidinium groups as bile acid sequestrants
US6558665B1 (en) * 1999-05-18 2003-05-06 Arch Development Corporation Encapsulating particles with coatings that conform to size and shape of the particles
US20020054903A1 (en) * 1999-10-19 2002-05-09 Joseph Tyler Direct compression polymer tablet core
US6733780B1 (en) * 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
DE19951116A1 (de) 1999-10-23 2001-04-26 Bosch Gmbh Robert Relais, insbesondere für eine Startvorrichtung
DE19962935A1 (de) † 1999-12-24 2001-06-28 Bayer Ag Verfahren zur Herstellung von vernetzten Ionenaustauschern auf Basis von ungesättigten, aliphatischen Nitrilen
AU780873B2 (en) * 2000-01-14 2005-04-21 Otsuka Pharmaceutical Factory, Inc. Inhibitors against sodium ion absorption, and preventive or therapeutic agents and foods containing the same
US6994827B2 (en) 2000-06-03 2006-02-07 Symyx Technologies, Inc. Parallel semicontinuous or continuous reactors
US6932990B2 (en) * 2000-08-01 2005-08-23 Oryza Oil & Fat Chemical Co., Ltd. Carbohydrate absorption inhibitor and method for manufacturing the same
US6908609B2 (en) * 2000-11-20 2005-06-21 Dow Global Technologies Inc. In vivo use of water absorbent polymers
US7033639B2 (en) * 2001-05-16 2006-04-25 Rohm And Haas Company Polyaniline coating composition
US6881484B2 (en) * 2001-05-30 2005-04-19 Mitsubishi Kagaku Iatron, Inc. Core-shell particle including signal-generating substance enclosed therein and process for producing the same
CA2516457C (en) * 2003-02-25 2011-12-06 Finnfeeds Finland Oy A simulated moving bed system and process
US7381428B2 (en) 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
US8282960B2 (en) * 2004-03-30 2012-10-09 Relypsa, Inc. Ion binding compositions
US7429394B2 (en) * 2004-03-30 2008-09-30 Relypsa, Inc. Ion binding compositions
US7854924B2 (en) * 2004-03-30 2010-12-21 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
US8192758B2 (en) * 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
US7556799B2 (en) † 2004-03-30 2009-07-07 Relypsa, Inc. Ion binding polymers and uses thereof
GB2430368B (en) * 2004-03-30 2009-08-26 Ilypsa Inc Methods and compositions for treatment of ion imbalances
WO2007038801A2 (en) † 2005-09-30 2007-04-05 Ilypsa, Inc. Monovalent cation-binding compositions comprising core-shell particles having crosslinked poly-vinylic shells, and methods of use thereof
CN101316601A (zh) * 2005-09-30 2008-12-03 伊立普萨公司 从哺乳动物的胃肠道选择性除去钾离子的方法和组合物
CN101321519A (zh) * 2005-09-30 2008-12-10 伊立普萨公司 制备含有交联壳的核-壳型复合物的方法及其得到的核-壳型复合物
EP2601981A1 (en) * 2007-08-29 2013-06-12 Sorbent Therapeutics, Inc. Absorbent polymeric compositions with varying counterion content and their methods of preparation and use
WO2010022380A2 (en) * 2008-08-22 2010-02-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
WO2010022381A1 (en) * 2008-08-22 2010-02-25 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
US20100111892A1 (en) * 2008-08-22 2010-05-06 Relypsa, Inc. Crosslinked polyfluoroacrylic acid and processes for the preparation thereof
CN103919792B (zh) † 2008-08-22 2018-03-09 瑞立普萨公司 交联阳离子交换聚合物、组合物及在治疗方法高钾血症中的应用

Also Published As

Publication number Publication date
CA2735058C (en) 2021-01-26
AU2009282721B2 (en) 2015-10-29
SMT201800660T1 (it) 2019-01-11
DK3431094T3 (da) 2023-02-20
LTPA2018016I1 (lt) 2019-01-10
CN102202670B (zh) 2014-04-30
PT3431094T (pt) 2023-03-03
MX389664B (es) 2025-03-20
CY1120930T1 (el) 2020-05-29
JP2012500806A (ja) 2012-01-12
LUC00094I2 (enExample) 2020-01-23
BRPI0917853A2 (pt) 2015-11-24
JP5883471B2 (ja) 2016-03-15
GB201222749D0 (en) 2013-01-30
KR101928973B1 (ko) 2018-12-13
EP4201408B1 (en) 2025-06-25
JP6232468B2 (ja) 2017-11-15
CY2019002I1 (el) 2020-05-29
ES2545887T5 (es) 2020-02-17
PT2365988E (pt) 2015-10-22
US20110236340A1 (en) 2011-09-29
JP2014144977A (ja) 2014-08-14
GB2495427A (en) 2013-04-10
EP4201408A1 (en) 2023-06-28
HRP20230091T1 (hr) 2023-03-17
LUC00094I1 (enExample) 2018-12-19
JP6890116B2 (ja) 2021-06-18
PL2365988T5 (pl) 2019-11-29
EP2365988B2 (en) 2019-07-03
GB2475657A (en) 2011-05-25
EP3431094B1 (en) 2022-12-07
KR102300471B1 (ko) 2021-09-30
EP2957286A1 (en) 2015-12-23
MX2011001893A (es) 2011-09-27
CY2019002I2 (el) 2020-05-29
JP5756403B2 (ja) 2015-07-29
HRP20181961T1 (hr) 2019-02-08
CA2735058A1 (en) 2010-02-25
HUE025934T2 (en) 2016-05-30
NO2018004I1 (no) 2018-01-17
JP2017218454A (ja) 2017-12-14
DE112009002063T5 (de) 2012-01-12
EP2957286B1 (en) 2018-11-21
GB2495426A (en) 2013-04-10
LTPA2018004I1 (lt) 2018-02-12
JP6633583B2 (ja) 2020-01-22
LTC2957286I2 (lt) 2019-11-25
ES2545887T3 (es) 2015-09-16
NL300962I2 (nl) 2020-06-02
SMT201500207T1 (it) 2015-10-30
GB201222750D0 (en) 2013-01-30
SI2957286T1 (sl) 2018-12-31
US20220000906A1 (en) 2022-01-06
KR20180133561A (ko) 2018-12-14
PL2365988T3 (pl) 2015-12-31
EP2365988B1 (en) 2015-07-22
KR20180014845A (ko) 2018-02-09
CY2018002I1 (el) 2019-07-10
BRPI0917853B8 (pt) 2020-04-22
DK2957286T3 (en) 2018-12-17
HRP20150955T1 (hr) 2015-10-09
GB2495427B (en) 2013-08-07
KR102150184B1 (ko) 2020-08-31
BRPI0917853C1 (pt) 2021-05-25
MX364398B (es) 2019-04-24
HUE071829T2 (hu) 2025-09-28
GB201222752D0 (en) 2013-01-30
PL4201408T3 (pl) 2025-09-22
AU2009282721A1 (en) 2010-02-25
DK2365988T3 (en) 2015-10-26
ES2699494T3 (es) 2019-02-11
EP2365988A2 (en) 2011-09-21
US20170165292A1 (en) 2017-06-15
EP3431094A1 (en) 2019-01-23
US20200289550A1 (en) 2020-09-17
CN103919792A (zh) 2014-07-16
NL300962I1 (nl) 2018-12-28
KR102178208B1 (ko) 2020-11-12
PL2957286T3 (pl) 2019-03-29
EP4201408C0 (en) 2025-06-25
HK1184675A1 (en) 2014-01-30
WO2010022383A3 (en) 2010-09-23
FI3431094T3 (fi) 2023-03-20
GB201104561D0 (en) 2011-05-04
ES2939021T3 (es) 2023-04-18
CN103919792B (zh) 2018-03-09
KR20200128600A (ko) 2020-11-13
GB2495428A (en) 2013-04-10
KR101825113B1 (ko) 2018-02-02
KR20110063647A (ko) 2011-06-13
NO2018041I1 (enExample) 2018-12-14
CN102202670A (zh) 2011-09-28
SI3431094T1 (sl) 2023-04-28
KR20200029614A (ko) 2020-03-18
HUS1900003I1 (hu) 2019-02-28
DK2365988T4 (da) 2019-10-07
JP2020172537A (ja) 2020-10-22
LT2957286T (lt) 2018-12-10
PL3431094T3 (pl) 2023-04-24
BRPI0917853B1 (pt) 2020-04-07
GB2475657B (en) 2013-05-29
PT2957286T (pt) 2018-11-30
WO2010022383A2 (en) 2010-02-25
LT3431094T (lt) 2023-02-27
HUE061320T2 (hu) 2023-06-28
ES3034535T3 (en) 2025-08-19
JP2019065030A (ja) 2019-04-25
JP2014144978A (ja) 2014-08-14
JP2016145256A (ja) 2016-08-12

Similar Documents

Publication Publication Date Title
HRP20250774T1 (hr) Umreženi polimeri za kationsku izmjenu, pripravci i upotreba u liječenju hiperkalemije
JP2017218454A5 (enExample)
JP2012500806A5 (enExample)
JP6817185B2 (ja) 高血圧症及び高カリウム血症を治療するためのカリウム結合剤
RU2015110825A (ru) Устойчивая к действию желудочного сока фармацевтическая или нутрицевтическая композиция со стойкостью к влиянию этанола
ES2585731T3 (es) Forma de dosificación farmacéutica que comprende nifedipino o nisoldipino y un antagonista de angiotensina II y/o un diurético
Yusif et al. Gastroretentive matrix tablets of boswellia oleogum resin: preparation, optimization, in vitro evaluation, and cytoprotective effect on indomethacin-induced gastric ulcer in rabbits
CN103906508A (zh) 治疗心血管疾病的方法
RU2018127317A (ru) Композиция быстрораспадающейся твердой лекарственной формы, включающая функционализированный карбонат кальция, и способ ее получения
HRP20110776T1 (hr) Stabilizirani farmaceutski sastavi koji sadrže fesoterodin
US9861585B2 (en) Osmotic floating tablets
JP2011241218A5 (enExample)
KR20140003376A (ko) 프레가발린의 경구투여용 제제
HRP20240720T1 (hr) Farmaceutski pripravak, koji sadrži čestice fosfatnog veziva
JPWO2009008480A1 (ja) 架橋ポリアリルアミン又はその酸付加塩、及びその医薬用途
RU2015110979A (ru) Комбинации ингибиторов sglt 2 и антигипертензивных лекарственных средств
RU2010153904A (ru) Ниацин-содержащие композиции с модифицированным высвобождением
AU2007205298A1 (en) Drug combinations
WO2010146408A3 (en) Nanoparticulate olmesartan medoxomil compositions, process for the preparation thereof and pharmaceutical compositions containing them
CN1187050C (zh) 内皮素拮抗剂和血管紧张肽原酶－血管紧张肽系统抑制剂的联合体系
ES2985514T3 (es) Medicamento polimérico para tratar la hiperpotasemia y método de preparación del mismo
MX2009009862A (es) Formas de dosificacion de liberacion prolongada/pulsatil en un tiempo especifico.
RS55786B1 (sr) Oralna formulacija za terapiju kardiovaskularnih bolesti
Fouladi et al. Preparation and in-vitro evaluation of gastroretentive bupropion hydrochloride tablets
CA2529351C (en) Use of prostaglandin i for enhancing the effect of a renin-angiotensin system inhibitor on a renal disease